TIGIT and neoplasm: PD-1 and TIGIT ligands are expressed widely within the tumor bed but combined PD-1 and TIGIT checkpoint blockade can significantly overcome the immunosuppressive effect of PD-1 and TIGIT engagement on T-cell function.